TransMedics (TMDX) Cash & Equivalents (2018 - 2026)

TransMedics' Cash & Equivalents history runs 9 years deep, the most recent figure standing at $461.7 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 48.87% year-over-year to $461.7 million in Q1 2026; TTM through Mar 2026 was $461.7 million, a 48.87% increase from a year earlier, with the FY2025 full-year figure at $488.4 million, up 45.07% from the prior year.
• Cash & Equivalents eased to $461.7 million in Q1 2026 per TMDX's latest filing, from $488.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $582.2 million in Q2 2023 and bottomed at $17.9 million in Q1 2022.
• The 5-year median for Cash & Equivalents is $350.2 million (2024), against an average of $329.2 million.
• Across the five-year window, Cash & Equivalents soared 1816.05% in 2023 and tumbled 37.69% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $201.2 million in 2022, then surged by 96.25% to $394.8 million in 2023, then fell by 14.73% to $336.6 million in 2024, then jumped by 45.07% to $488.4 million in 2025, then fell by 5.46% to $461.7 million in 2026.
• Per Business Quant, the three latest TMDX Cash & Equivalents figures stand at $461.7 million (Q1 2026), $488.4 million (Q4 2025), and $466.2 million (Q3 2025).